drugset / Trial / NCT03237182

The Individualized M(X) Drug-resistant TB Treatment Strategy Study

NCT03237182

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized controlled clinical trial comparing treatment success of a gene-derived individualized drug-resistant Tuberculosis regimen to a standard Tuberculosis regimen based on South African National Tuberculosis guidelines.

Timeline

Start
2017-06-14
Primary completion
2022-12-19
Completion
2022-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Amikacin Small molecule
Subject Azithromycin Small molecule
Subject Bedaquiline Small molecule
Subject Capreomycin Protein / enzyme biologic
Subject Clarithromycin Small molecule
Subject Clofazimine Small molecule
Subject Cycloserine Small molecule
Subject Ethambutol Small molecule
Subject Ethionamide Small molecule
Subject Gatifloxacin Small molecule
Subject Isoniazid Small molecule
Subject Kanamycin Small molecule
Subject Levofloxacin Small molecule
Subject Linezolid Other / unclassified
Subject Meropenem Small molecule
Subject Moxifloxacin Small molecule
Subject Ofloxacin Small molecule
Subject Pretomanid Small molecule
Subject Protionamide Small molecule
Subject Pyrazinamide Small molecule
Subject Rifabutin Small molecule
Subject Rifampin Small molecule
Subject Sutezolid Small molecule
Subject Terizidone Small molecule
Subject amithiozone Small molecule
Subject amoxicillin/clavulanate Unknown
Subject delaminid Unknown
Subject imipenem/cilastatin Unknown
Subject para-aminosalicylic acid Unknown
Subject streptomycin Other / unclassified